GlassScriptPhysician profile
Prateek V Dalal
NPI 1184612723
$3,094.03
in general payments reported to CMS, 2019-2025
21 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $247 · 2021: $168 · 2022: $473 · 2023: $197 · 2024: $824 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $570.70 | 2021-2024 | Amplatzer, Mitraclip |
| Novartis Pharmaceuticals Corporation | $334.76 | 2019-2020 | |
| Medtronic Vascular, INC. | $288.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.19 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $241.45 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $232.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $147.35 | 2022-2023 | Xarelto |
| Amarin Pharma, INC. | $126.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Atricure, INC. | $117.24 | 2022 | |
| Astellas Pharma US INC | $99.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $98.20 | 2022-2024 | Airsupra |
| Novo Nordisk INC | $95.35 | 2024 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $90.80 | 2025 | Symplicity G3 |
| Heartflow, INC. | $66.43 | 2023 | Ffrct |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $63.93 | 2024 | Barostim Neo System |
| Abiomed | $56.85 | 2025 | |
| Philips North America LLC | $38.14 | 2024 | (5091) Amb Mon & Diag Und |
| Esperion Therapeutics, INC. | $23.44 | 2025 | Nexletol |
| Pfizer INC. | $15.91 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prateek Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.